The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Adults with Prediabetes or Diabetes.
*This study is now fully enrolled and no additional subjects are currently being recruited.
GLP1 and Aging
Purpose of this Study
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects Semaglutide has on people who take the drug and the drug’s effect on physical function, body composition, and aging.
You may qualify if:
- Older than 65
- Have prediabetes or diabetes
- Living independently (not in assisted living or nursing home)
You may NOT qualify if:
- Have heart disease
- Have liver disease
- Smoke
Duration of the Study
The study involves 8 study visits over the course of approximately 6 months.
Study Procedures
- Medical history
- Physical performance
- Blood tests
- Fat and muscle biopsies
- X-ray for body composition
Location
UT Health San Antonio
Sam and Ann Barshop Institute for Longevity and Aging Studies
4939 Charles Katz Dr.
San Antonio, TX 78229
Compensation
You may receive up to $425 for the completion of this study.
Clinical Research Team
Principal Investigator: Tiffany M. Cortes, MD
